copay assistance actimmune interferon gamma 1b

#Copay assistance actimmune interferon gamma 1b trial#

If a severe adverse reaction (e.g., flu-like symptoms) occurs, reduce dosage by 50% or discontinue drug until adverse reaction abates. Osteopetrosis Sub-Qĥ0 mcg/m 2 (1 million international units per m 2) 3 times weekly for patients with body surface area >0.5 m 2 and 1.5 mcg/kg 3 times weekly for those with body surface area ≤0.5 m 2. Pediatric Patients Chronic Granulomatous Disease Sub-Qĥ0 mcg/m 2 (1 million international units per m 2) 3 times weekly for patients with body surface area (BSA) >0.5 m 2 and 1.5 mcg/kg 3 times weekly for those with body surface area ≤0.5 m 2. DosageĮach mg of interferon gamma-1b is approximately equivalent to 20 million international units (equivalent to the amount that formerly was expressed as 30 million units). Vials contain no preservative discard any residual solution remaining in the vial after administration of the single dose.

To minimize risk of flu-like syndrome, administer at bedtime and/or give acetaminophen to prevent or partially alleviate fever and headache. Optimum sites for sub-Q injection include right and left deltoid and anterior thigh. If home use is prescribed, carefully instruct patients and/or their caregivers in appropriate use provide a puncture-resistant container for proper, safe disposal of used syringes and needles.Īdminister by sub-Q injection 3 times weekly (e.g., Monday, Wednesday, Friday). Related/similar drugs Ofev, nintedanib, pirfenidone, Esbriet, methoxsalen, romidepsin, bexarotene Interferon Gamma Dosage and Administration General

#Copay assistance actimmune interferon gamma 1b trial#

FDA suggests that health-care professionals should discuss the results of this trial with their patients receiving the drug for IPF and carefully consider whether they should continue to receive treatment with interferon gamma-1b. Interferon gamma-1b is not approved for use in patients with IPF. Interim analysis also indicated that 14.5% of patients receiving interferon gamma 1-b died compared with 12.7% of those receiving placebo. Interferon gamma-1b was investigated in patients with idiopathic pulmonary fibrosis † (IPF) with mild-to-moderate lung function impairment in the INSPIRE study the study was terminated early when interim data analysis indicated lack of benefit in patients receiving the drug. Treatment to delay the time to disease progression in patients with severe, malignant osteopetrosis (designated an orphan drug by FDA for this use). Reduction of the frequency and severity of serious infections in patients with chronic granulomatous disease (designated an orphan drug by FDA for this use). Uses for Interferon Gamma Chronic Granulomatous Disease Written by ASHP.īiologic response modifier biosynthetic (recombinant DNA origin) form of endogenous human interferon gamma. Chemical name: N2-l-Methionyl-1-139-interferonγ (human lymphocyte protein moiety reduced)